The generic name of Goserelin is Goserelin Acetate Extended-Release Implant, and there is no uniform standard for its course of use, so there is no indication of any difference between using it for 28 days or three months for the time being. Clinical treatment should be based on the patient’s specific situation to develop the appropriate treatment program and course of treatment. Goserelin acetate extended-release implant is suitable for prostate cancer that can be treated with hormone therapy. In clinical application, it is usually injected subcutaneously into the anterior abdominal wall of adult men (including the elderly) once every 12 weeks. However, it is not indicated for use in women and children. Common clinical adverse reactions include hot flashes, excessive sweating, sexual dysfunction and injection site reactions. Goserelin acetate is contraindicated in patients with known hypersensitivity to the active ingredient or to other GnRH analogs, and to any of the other excipients. The use of goserelin acetate extended-release implant must be supervised by a physician and administered in an aseptic manner. Instructions for proper use can be found on the instruction card in the package.